Previous preclinical study has also demonstrated that inhibition of proteasomes could induce HIF1α and VEGF production in malignant GSCs, thus suggesting that co-inhibition of the proteasome and VEGF could achieve better tumour inhibition [289]. The gene discussed is VEGFA; the disease is neoplasm.